Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Total Current Liabilities
All obligations due within one year.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities falls 13.0% from a year ago
Total current liabilities stood at $7.87M at the end of Q3 FY2026, down 13.0% from a year earlier and down 9.9% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Total current liabilities amounted to 2.5% of total assets at the end of Q3 FY2026, down 2.0 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -13.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.75M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- -6.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.75M | -7.2% |
| FY2024 | 2024-12-31 | 10.51M | +80.4% |
| FY2023 | 2023-12-31 | 5.82M | -56.5% |
| FY2022 | 2022-12-31 | 13.4M | +5.3% |
| FY2021 | 2021-12-31 | 12.72M | — |
Total Current Liabilities vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.0% is the 7th highest of 8, against a peer median of +42.9%.
- Total current liabilities amounts to 2.5% of total assets for TRVI, versus a peer median of 6.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $332.22M USD | -6.8% | +30.2% | 18.5% | |
| Jun 2026 | $189.3M USD | +141.4% | +148.9% | 36.3% | |
| Mar 2026 | $31.78M USD | +0.9% | +10.1% | 6.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M USD | +90.7% | +125.4% | 3.6% |
UPBUpstream Bio, Inc. | Mar 2026 | $13.67M USD | +42.9% | +40.4% | 4.3% |
| Mar 2026 | $9.9M USD | -91.1% | -3.4% | 3.7% | |
| Mar 2026 | $8.49M USD | +206.6% | +57.0% | 6.9% | |
| Sep 2026 | $7.87M USD | -13.0% | -10.1% | 2.5% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 7.53M SEK | — | — | 7.9% |
| Peer median (excluding TRVI) | — | +42.9% | +40.4% | 6.8% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.83M | 12.59M | 32.4M | 34.1M | 18.91M |
| Short-term Investments | 0 | 107.92M | 50.57M | 73.53M | 169.35M |
| Net Receivables | 241K | 0 | 0 | 532K | 986K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.31M | 955K | 335K | 1.15M |
| Total Current Assets | 37.96M | 122.62M | 87.55M | 109.43M | 191.66M |
| Property, Plant & Equipment (Net) | 184K | 194K | 1.56M | 1.23M | 855K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 334K | 205K | 297K | 243K | 928K |
| Total Non-current Assets | 518K | 399K | 1.86M | 1.47M | 1.78M |
| Total Assets | 38.48M | 123.02M | 89.4M | 110.9M | 193.44M |
| Account Payables | 2.85M | 2.86M | 1.81M | 3.41M | 3.91M |
| Short-term Debt | 5.83M | 7M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 114K | 1.51M | 1.61M | 2.54M | 2.75M |
| Total Current Liabilities | 12.72M | 13.4M | 5.82M | 10.51M | 9.75M |
| Long-term Debt | 8.65M | 2.15M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 3K | 0 | 0 | 0 |
| Total Non-current Liabilities | 8.68M | 2.16M | 1.03M | 747K | 446K |
| Total Liabilities | 21.4M | 15.56M | 6.86M | 11.26M | 10.2M |
| Common Stock | 29K | 60K | 68K | 94K | 128K |
| Retained Earnings | (180.92M) | (210.07M) | (239.13M) | (287.05M) | (329.8M) |
| Accumulated OCI | 0 | (122K) | (29K) | 61K | 148K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 17.08M | 107.46M | 82.55M | 99.64M | 183.24M |
| Total Debt | 14.63M | 9.18M | 1.34M | 1.03M | 753K |
| Net Debt | (22.2M) | (3.41M) | (31.06M) | (33.07M) | (18.16M) |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.